crizotinib Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4187 877399-52-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • crizotinib
  • xalkori
  • PF 02341066
  • PF-02341066
Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d'Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the gene's expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.
  • Molecular weight: 450.34
  • Formula: C21H22Cl2FN5O
  • CLOGP: 4.29
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 77.99
  • ALOGS: -4.87
  • ROTB: 5

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 23, 2012 EMA
Aug. 26, 2011 FDA PF PRISM CV

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 2968.44 52.62 814 5298 40197 4592683
Neoplasm progression 1891.93 52.62 422 5690 8433 4624447
Death 1758.31 52.62 828 5284 197335 4435545
Non-small cell lung cancer 1253.08 52.62 222 5890 1208 4631672
Nausea 1099.53 52.62 585 5527 176748 4456132
Lung neoplasm malignant 1069.65 52.62 254 5858 6652 4626228
Diarrhoea 740.60 52.62 428 5684 149757 4483123
Visual impairment 697.40 52.62 227 5885 19233 4613647
Vomiting 631.02 52.62 357 5755 119342 4513538
Neoplasm malignant 529.44 52.62 161 5951 10860 4622020
Oedema peripheral 514.21 52.62 223 5889 41749 4591131
Constipation 483.94 52.62 214 5898 41940 4590940
Photopsia 402.80 52.62 87 6025 1445 4631435
Pleural effusion 355.93 52.62 147 5965 24251 4608629
Fatigue 329.39 52.62 257 5855 145309 4487571
Interstitial lung disease 321.73 52.62 128 5984 19157 4613723
Decreased appetite 316.21 52.62 176 5936 56221 4576659
Dysgeusia 306.41 52.62 115 5997 14704 4618176
Pneumonitis 287.27 52.62 97 6015 9113 4623767
Pneumonia 234.97 52.62 183 5929 102632 4530248
Dysphagia 233.67 52.62 111 6001 25420 4607460
Oedema 233.28 52.62 101 6011 18650 4614230
Oesophagitis 231.82 52.62 68 6044 4020 4628860
Pulmonary embolism 219.06 52.62 117 5995 34309 4598571
Dyspnoea 202.29 52.62 191 5921 138794 4494086
Renal impairment 201.23 52.62 100 6012 25238 4607642
Product use issue 193.47 52.62 97 6015 24939 4607941
Vitreous floaters 188.19 52.62 48 6064 1671 4631209
Alanine aminotransferase increased 157.03 52.62 88 6024 28285 4604595
Asthenia 155.74 52.62 134 5978 86029 4546851
Vision blurred 153.99 52.62 83 6029 24720 4608160
Dizziness 152.16 52.62 141 5971 99730 4533150
Renal abscess 150.20 52.62 29 6083 264 4632616
Peripheral swelling 148.28 52.62 83 6029 26609 4606271
Dehydration 143.71 52.62 96 6016 42194 4590686
Neutropenia 137.39 52.62 98 6014 47852 4585028
Aspartate aminotransferase increased 137.02 52.62 77 6035 24861 4608019
Lung adenocarcinoma 134.83 52.62 36 6076 1501 4631379
Transaminases increased 133.42 52.62 56 6056 9550 4623330
Bradycardia 133.06 52.62 73 6039 22496 4610384
Electrocardiogram QT prolonged 117.27 52.62 59 6053 15236 4617644
Hepatic enzyme increased 113.83 52.62 61 6051 17930 4614950
Embolism 111.95 52.62 37 6075 3238 4629642
Pericardial effusion 111.74 52.62 47 6065 8051 4624829
Renal cyst 111.67 52.62 34 6078 2279 4630601
Respiratory failure 110.61 52.62 72 6040 30254 4602626
Blood creatinine increased 108.35 52.62 68 6044 26832 4606048
Second primary malignancy 104.94 52.62 34 6078 2794 4630086
Anaemia 104.87 52.62 99 6013 71461 4561419
Product use in unapproved indication 104.59 52.62 65 6047 25208 4607672
Hepatic function abnormal 102.84 52.62 53 6059 14383 4618497
Dyspepsia 97.54 52.62 53 6059 16001 4616879
Hypoalbuminaemia 97.19 52.62 33 6079 3137 4629743
Malaise 96.08 52.62 105 6007 90052 4542828
Cardiac failure 95.13 52.62 63 6049 27225 4605655
Hepatotoxicity 94.30 52.62 42 6070 8257 4624623
Cough 93.27 52.62 83 6029 55504 4577376
Hypoxia 92.96 52.62 48 6064 13073 4619807
Non-small cell lung cancer metastatic 91.30 52.62 19 6093 260 4632620
Deep vein thrombosis 89.21 52.62 59 6053 25435 4607445
Renal failure 88.36 52.62 71 6041 41298 4591582
Liver function test abnormal 87.85 52.62 48 6064 14644 4618236
Pyrexia 87.77 52.62 109 6003 107035 4525845
Stomatitis 84.93 52.62 49 6063 16590 4616290
Acute kidney injury 74.90 52.62 82 6030 70349 4562531
Diplopia 74.41 52.62 33 6079 6418 4626462
Lung adenocarcinoma stage IV 73.56 52.62 14 6098 117 4632763
Oesophageal ulcer 72.39 52.62 22 6090 1464 4631416
Swelling 72.22 52.62 51 6061 24431 4608449
General physical health deterioration 71.42 52.62 54 6058 28724 4604156
Non-small cell lung cancer stage IV 70.86 52.62 14 6098 145 4632735
Hepatitis 70.54 52.62 39 6073 12166 4620714
Weight decreased 67.83 52.62 69 6043 54395 4578485
Liver function test increased 67.61 52.62 29 6083 5205 4627675
Metastases to central nervous system 67.29 52.62 27 6085 4097 4628783
Malignant neoplasm progression 66.61 52.62 52 6060 28984 4603896
Lung cancer metastatic 64.65 52.62 19 6093 1126 4631754
Febrile neutropenia 64.46 52.62 49 6063 26263 4606617
Thrombocytopenia 64.15 52.62 63 6049 47610 4585270
Hypotension 62.33 52.62 73 6039 67327 4565553
Off label use 62.17 52.62 102 6010 129011 4503869
Abdominal discomfort 61.13 52.62 49 6063 28359 4604521
Rash 59.57 52.62 91 6021 108297 4524583
Hypoaesthesia 56.48 52.62 49 6063 31616 4601264
Gastrooesophageal reflux disease 55.81 52.62 36 6076 14857 4618023
Multiple-drug resistance 55.53 52.62 15 6097 653 4632227
Ileus 54.89 52.62 25 6087 5171 4627709
Visual field defect 54.78 52.62 21 6091 2824 4630056
Renal cyst infection 54.11 52.62 10 6102 70 4632810
Fluid retention 53.95 52.62 32 6080 11389 4621491
Thrombosis 53.47 52.62 38 6074 18366 4614514
White blood cell count decreased 52.67 52.62 48 6064 33017 4599863

Pharmacologic Action:

SourceCodeDescription
ATC L01XE16 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:59163 biomarker
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
FDA MoA N0000020000 Receptor Tyrosine Kinase Inhibitors
FDA MoA N0000182139 Cytochrome P450 2B6 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000191265 Organic Cation Transporter 1 Inhibitors
FDA MoA N0000187061 Organic Cation Transporter 2 Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer indication 254637007 DOID:3908

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.74 Basic
pKa2 6.14 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200MG XALKORI PF PRISM CV N202570 Aug. 26, 2011 RX CAPSULE ORAL 7825137 May 12, 2027 TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
250MG XALKORI PF PRISM CV N202570 Aug. 26, 2011 RX CAPSULE ORAL 7825137 May 12, 2027 TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
200MG XALKORI PF PRISM CV N202570 Aug. 26, 2011 RX CAPSULE ORAL March 11, 2023 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
250MG XALKORI PF PRISM CV N202570 Aug. 26, 2011 RX CAPSULE ORAL March 11, 2023 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
ALK tyrosine kinase receptor Kinase INHIBITOR Ki 9.13 CHEMBL CHEMBL
Hepatocyte growth factor receptor Kinase INHIBITOR Kd 9.26 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 8 CHEMBL
Epidermal growth factor receptor Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase DCLK1 Kinase Kd 6.48 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.64 CHEMBL
Vascular endothelial growth factor receptor 1 Kinase Kd 5.64 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 6.25 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 6.21 CHEMBL
Insulin receptor Kinase AGONIST Kd 6.47 CHEMBL
SRSF protein kinase 1 Kinase Kd 5.74 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2 Kinase Kd 5.40 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 5.40 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.48 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 6.05 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 6.24 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 6.54 CHEMBL
Serine/threonine-protein kinase NIM1 Kinase Kd 5.34 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.55 CHEMBL
Aurora kinase A Kinase Kd 6.59 CHEMBL
Tyrosine-protein kinase JAK1 Kinase Kd 6.48 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 5.70 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 5.60 CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 5.11 CHEMBL
Cyclin-dependent kinase 11B Kinase Kd 6.12 CHEMBL
Serine/threonine-protein kinase D1 Kinase Kd 6 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 6.64 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.16 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase Nek7 Kinase Kd 5.24 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.41 CHEMBL
AarF domain-containing protein kinase 4 Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.17 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 6.29 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 5.74 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.54 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 6.55 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 7 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 6.15 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.36 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 6.57 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 7.22 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 5.64 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 6.70 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 6.11 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.96 CHEMBL
Aurora kinase C Kinase Kd 5.37 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 7.02 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 5.43 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 6.11 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 5.44 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase DCLK2 Kinase Kd 6.43 CHEMBL
Misshapen-like kinase 1 Kinase Kd 5.36 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 5.44 CHEMBL
Insulin receptor-related protein Kinase Kd 6.22 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 6.10 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 6.13 CHEMBL
Insulin-like growth factor 1 receptor Kinase Kd 6.11 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 7.19 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 5.82 CHEMBL
Aurora kinase B Kinase Kd 7.12 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.74 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 6.64 CHEMBL
Macrophage-stimulating protein receptor Kinase Kd 7.60 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 6.68 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 7.31 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 6.24 CHEMBL
Ephrin type-A receptor 7 Kinase Kd 6.33 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 6 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit beta Kinase Kd 5.26 CHEMBL
Serine/threonine-protein kinase Nek9 Kinase Kd 6.10 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 6.05 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.03 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 5.62 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Kd 5.44 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 6 CHEMBL
LIM domain kinase 1 Kinase Kd 6.08 CHEMBL
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) Kinase IC50 7.29 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 5.80 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 6.44 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 6.92 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 6.12 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 7.12 CHEMBL
Dual specificity testis-specific protein kinase 1 Kinase Kd 6.42 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.51 CHEMBL
NT-3 growth factor receptor Kinase Kd 7.09 CHEMBL
Tyrosine-protein kinase ZAP-70 Kinase Kd 5.38 CHEMBL
Activin receptor type-1 Kinase Kd 6.36 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 7.51 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 5.38 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 7.14 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 5.17 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 6.34 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 5.55 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 6.72 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.96 CHEMBL
Angiopoietin-1 receptor Kinase Kd 6.57 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 6.15 CHEMBL
Peripheral plasma membrane protein CASK Kinase Kd 6.85 CHEMBL
Dual serine/threonine and tyrosine protein kinase Kinase Kd 6.35 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase Kd 8.39 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 8.22 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 6.70 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 6.31 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.96 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.48 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 5.48 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.89 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 6.68 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 6.62 CHEMBL
Activin receptor type-1B Kinase Kd 6.07 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 6.96 CHEMBL
TGF-beta receptor type-1 Kinase Kd 6 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 5.89 CHEMBL
Myotonin-protein kinase Kinase Kd 5.85 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 6.29 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 6.10 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 6.35 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 7.52 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 7.92 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 6.01 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 8.11 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 7.43 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.92 CHEMBL
SRSF protein kinase 3 Kinase Kd 5.09 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 6.07 CHEMBL
LIM domain kinase 2 Kinase Kd 6.16 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 6.77 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 5.80 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 5.49 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.96 CHEMBL
Cyclin-dependent kinase 11A Kinase Kd 6.38 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 5.21 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 6.19 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 6 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 5.68 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 7.10 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 8.44 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 6.29 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 6.68 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.49 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 5.68 CHEMBL
Angiopoietin-1 receptor Kinase IC50 6.35 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 5.94 CHEMBL
Macrophage-stimulating protein receptor Kinase IC50 7.10 CHEMBL

External reference:

IDSource
D000077547 MESH_DESCRIPTOR_UI
4030983 VUID
N0000183253 NUI
C2974289 UMLSCUI
D09731 KEGG_DRUG
53AH36668S UNII
9301 INN_ID
703638005 SNOMEDCT_US
1148495 RXNORM
013917 NDDF
28080 MMSL
d07800 MMSL
4030983 VANDF
703637000 SNOMEDCT_US
11626560 PUBCHEM_CID
CHEBI:64310 CHEBI
CHEMBL601719 ChEMBL_ID
VGH PDB_CHEM_ID
DB08865 DRUGBANK_ID
4903 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xalkori HUMAN PRESCRIPTION DRUG LABEL 1 0069-8140 CAPSULE 250 mg ORAL NDA 17 sections
Xalkori HUMAN PRESCRIPTION DRUG LABEL 1 0069-8141 CAPSULE 200 mg ORAL NDA 17 sections